Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Classifica tra le azioni #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Prezzo delle azioni
$0.1502
Ultima sincronizzazione: 2024-11-04
Capitalizzazione di mercato
$6.43M
Variazione (1 giorno)
-5.45%
Variazione (1 anno)
0.00%
Paese
US
Scambia Renalytix Plc (RNLX)

Categoria

Healthcare
Utile per Renalytix Plc (RNLX)
Utile nel Sep 2024 TTM: $-28.67M
Secondo gli ultimi rapporti finanziari di Renalytix Plc, gli utili attuali della società sono $-28.67M. Nel 2023, la società ha registrato un utile di $-46.22M, una diminuzione rispetto a agli utili del 2022, che erano di $-45.25M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Renalytix Plc dal 2018 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-28.67M -14.29%
2024 $-33.45M -27.63%
2023 $-46.22M 2.14%
2022 $-45.25M 26.44%
2021 $-35.79M 237.30%
2020 $-10.61M 62.78%
2019 $-6.52M 1,459.33%
2018 $-418.00K 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
$2.04B -7,225.67%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
$222.34M -875.49%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
$295.53M -1,130.77%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
$-259.89M 806.47%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
- -
US